Sarah Reed is the General Counsel at RA Capital Management. Sarah joined RA from MPM Capital where she served as the COO & General Counsel. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Sarah began her legal career with Foley, Hoag, & Eliot LLP. […]
Team Role: Board Of Directors
Fouad Namouni, MD
Fouad Namouni, MD brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Since September 2020, he has served as President of Research & Development at Blueprint Medicines, providing key leadership as the company built a fully integrated global business and overseeing all […]
Erez Kalir
Erez Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. He currently serves as the Managing Member of Martial Eagle Fund and as a Venture Partner at FJ Labs, renowned for its leadership in early-stage venture investments. He also authors the influential […]
Michel Detheux
Michel Detheux is the President, and Chief Executive Officer at iTeos Therapeutics. He has held the role of Chief Executive Officer since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded […]
Alexander (Bo) Cumbo
Mr. Cumbo has served as Solid’s President and Chief Executive Officer and as a director since December 2022. Mr. Cumbo served as the President and Chief Executive Officer and member of the Board of directors for AavantiBio from October 2020 until December 2022.From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility […]
Daniella Beckman
Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. […]
Jean-Paul Kress, M.D.
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation […]